MAI Capital Management
FHTX icon

MAI Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

MAI Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35
Closed -$168 – 2981
2026
Q1 		$168 Buy
+35
New +$192 ﹤0.01% 4656

Other funds holding FHTX

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

MAI Capital Management's FHTX Position: Q2 2026 in Review

MAI Capital Management sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 35 shares — an estimated $168 sold.

MAI Capital Management first reported a position in FHTX in Q1 2026 and held it in 1 quarter. The position peaked at $168 in Q1 2026. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • MAI Capital Management reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 35 Foghorn Therapeutics shares in Q2 2026, an estimated $168.
  • MAI Capital Management first reported a position in Foghorn Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Foghorn Therapeutics position peaked at $168 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.